Viridian Therapeutics, Inc. (VRDN) is a Biotechnology company in the Healthcare sector, currently trading at $15.19. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Analyst consensus target is VRDN = $43 (+183.7% upside).
Valuation: VRDN trades at a trailing Price-to-Earnings (P/E) of -3.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.
Financials: revenue is $71M, +7757.9%/yr average growth. Net income is $343M (loss), growing at -43.3%/yr. Net profit margin is -483.6% (negative). Gross margin is 98.4% (+41 pp trend).
Balance sheet: total debt is $51M against $722M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 12.65 (strong liquidity). Debt-to-assets is 5.6%. Total assets: $899M.
Analyst outlook: 13 / 16 analysts rate VRDN as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
